Home

ANASTASIOS GIANAKAKOS

CIK 1413822 · President & CEO · last filed 2026-06-22

ANASTASIOS GIANAKAKOS is a President & CEO who has filed 123 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for KARD, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$17.5M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

123

Lifetime Open-Market Net

-$17.46M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KARD President & CEO 548,513 — — $0 1 2026-06-22
LianBio (LIAN) Delisted Director 382,471 $0.32 $122.0K $0 4 2024-02-20
MyoKardia, Inc. (MYOK) Delisted President and CEO 72,209 — — -$13.62M 64 2020-07-07
MAPP SVP, Chief Business Officer 0 $27.50 $0 -$3.84M 53 2013-03-04

Recent Filings

123 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-22 KARD Conv (C) +568,395 $0 EDGAR
2024-02-20 LianBio (LIAN) Delisted Mixed +17,082 -$2 EDGAR
2023-06-23 LianBio (LIAN) Delisted Grant (A) — $0 EDGAR
2022-06-27 LianBio (LIAN) Delisted Grant (A) — $0 EDGAR
2022-01-03 LianBio (LIAN) Delisted Exer (M) +36,548 $237.2K EDGAR
2020-11-19 — Mixed −747,073 $0
2020-07-07 MyoKardia, Inc. (MYOK) Delisted Sell (S) −5,000 -$469.9K EDGAR
2020-06-04 MyoKardia, Inc. (MYOK) Delisted Sell (S) −5,000 -$514.2K EDGAR
2020-05-20 MyoKardia, Inc. (MYOK) Delisted Sell (S) −10,000 -$1.25M EDGAR
2020-05-13 MyoKardia, Inc. (MYOK) Delisted Sell (S) −25,000 -$2.55M EDGAR
Showing 1–10 of 123
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.